A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

This real-world study is following patients with advanced lung cancer that has a specific genetic change called "ALK-positive" who are being treated with a drug called ensartinib. The goal is to understand how well the drug works and what side effects occur outside of a controlled clinical trial setting. **You may be eligible if...** - You have advanced (stage IIIB or IV) non-small cell lung cancer with an ALK-positive mutation - Your cancer has progressed during or after a prior ALK-targeted therapy - You have an acceptable level of physical functioning (ECOG 0–2) - Your disease may benefit from radiation to certain areas (bone, lung, adrenal) **You may NOT be eligible if...** - You have not had prior ALK-targeted treatment - Your general health or lab results are not adequate for treatment Talk to your doctor to see if this trial is right for you.